Sphingolipids are essential components of all eukaryotic membranes. The bioactive
sphingolipid molecule, Sphingosine 1-Phosphate (S1P), regulates various important …

Ozanimod (Zeposia®), an orally administered sphingosine 1-phosphate (S1P) receptor
modulator (S1PRM) that is selective for the S1P1 and S1P5 receptor subtypes, is approved …

In recent years, newly emerging therapies, such as immune checkpoint inhibitors and
antibody-drug conjugates, have further improved outcomes for breast cancer patients …

Introduction Fingolimod is a disease-modifying therapy for multiple sclerosis (MS) that
modulates sphingosine 1-phospate receptors, impeding the egress of lymphocytes from …

Introduction Spinal muscular atrophy (SMA) is a severe genetic neuromuscular disease
characterized by a loss of motor neurons and progressive muscle weakness. Children with …

Background: Several oral disease-modifying therapies (DMTs) have been approved by the
Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis …

Sphingosine 1-phosphate receptor (S1PR) modulators represent one of the main classes of
disease-modifying therapies (DMTs) used for multiple sclerosis (MS) treatment [1]. The …

Introduction Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral
disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No …

As an understanding of the mechanisms underlying the pathogenesis of multiple sclerosis
(MS) grows, in particular in those immune-related, novel therapeutic approaches have …